PitchSend

Ginkgo Results Presentation Deck

New partnership with Aldevron has potential to generate substantial near-term royalties Foundry Ginkgo conducted VCE R&D work pro-bono upon discovering supply chain. bottlenecks as part of COVID-19 response programs + Downstream Value CASE STUDY 2 aldevron Ginkgo receives a royalty on sales, in a tiered structure with rates increasing as process improvements are achieved. With breakthrough process improvements, the royalty rates are meaningful and far exceed typical rates in the biopharma industry. Aldevron expects to begin selling product in 2021 and as mRNA modalities continue to grow, program has potential to generate strong recurring revenues. H1 UPDATE | AUGUST 2021 GINKGO BIOWORKS 20

View entire presentation